

MEDICARE ELIGIBLE INDICATIONS AND CRITERIA (PLEASE TICK)

	MBS ITEM	INDICATIONS	
LUNGS	61523	<input type="checkbox"/> Evaluation of solitary nodule where the lesion is considered unsuitable for biopsy, or for which biopsy has failed.	Diagnosis
	61529	<input type="checkbox"/> Staging of proven NSCLC, where curative surgery or R/T is planned.	Staging
BREAST	61524	<input type="checkbox"/> Staging of locally advanced (stage III) breast cancer for a patient who is considered suitable for active therapy.	Staging
	61525	<input type="checkbox"/> Evaluation of suspected metastatic or suspected locally or regionally recurrent breast carcinoma, for a patient who is considered suitable for active therapy.	Restaging
GIT	61541	<input type="checkbox"/> Following initial therapy, for the evaluation of suspected residual, metastatic, or recurrent colorectal carcinoma in patients considered suitable for active therapy.	Restaging
	61577	<input type="checkbox"/> Staging of proven oesophageal or GEJ carcinoma, in patients who are considered suitable for active therapy.	Staging
MELANOMA	61553	<input type="checkbox"/> Following initial therapy, for the evaluation of suspected metastatic or recurrent malignant melanoma in patients considered suitable for active therapy.	Restaging
GYNAE	61565	<input type="checkbox"/> Following initial therapy, for the evaluation of suspected residual, metastatic, or recurrent ovarian carcinoma in patients considered suitable for active therapy	Restaging
	61571	<input type="checkbox"/> Further primary staging of patients with histologically proven carcinoma of the uterine cervix, at FIGO stage IB2 or greater by conventional staging, prior to planned radical R/T or a combined modality therapy with curative intent.	Staging
	61575	<input type="checkbox"/> Further staging of patients with confirmed local recurrence of carcinoma of the uterine cervix considered suitable for salvage pelvic chemoradiotherapy or pelvic exenteration with curative intent.	Restaging
HEAD & NECK	61598	<input type="checkbox"/> Staging of biopsy proved newly diagnosed or recurrent head and neck cancer.	Staging
	61604	<input type="checkbox"/> Evaluation of patients with suspected residual head and neck cancer after definitive treatment, and who are suitable for active therapy.	Restaging
	61610	<input type="checkbox"/> Evaluation of squamous cell carcinoma of unknown primary site involving cervical nodes.	Staging
LYMPHOMA	61620	<input type="checkbox"/> Initial staging of newly diagnosed or previously untreated Hodgkin or non-Hodgkin lymphoma.	Staging
	61622	<input type="checkbox"/> Assess response to first line therapy either during treatment or within 3 months of completing definitive first line treatment for Hodgkin or non-Hodgkin lymphoma.	Post Therapy
	61628	<input type="checkbox"/> Restaging following confirmation of recurrence of Hodgkin or non-Hodgkin lymphoma.	Restaging
	61632	<input type="checkbox"/> Assess response to second-line chemotherapy is haemopoietic stem cell transplantation is being considered for Hodgkin or non-Hodgkin lymphoma.	Post Therapy
SARCOMA	61640	<input type="checkbox"/> Initial staging of patients with biopsy proven bone or soft tissue sarcoma (excluding gastrointestinal and stroma tumour) considered by conventional staging to be potentially curable.	Staging
	61646	<input type="checkbox"/> Evaluation of patients with suspected residual or recurrent sarcoma (excluding gastrointestinal and stroma tumour) after the initial course of definitive therapy to determine suitability for subsequent therapy with curative intent.	Restaging
BRAIN	61560	<input type="checkbox"/> Performed for the diagnosis of Alzheimer's disease. <u>3 per lifetime</u> and no more than <u>1 every 12 months</u> .	Diagnosis
RARE	61612	<input type="checkbox"/> Initial staging of cancer, for a patient who is considered suitable for active therapy, if: a) the cancer is a typically FDG-avid cancer; and (b) there is at least 10% likelihood that a PET study result will inform a significant change in management for the patient	Staging
	61614	<input type="checkbox"/> Following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent cancer in a patient who is undergoing, or is suitable for, active therapy, if the cancer is a typically FGD-avid cancer	Restaging
PROSTATE	61563	<input type="checkbox"/> Initial staging of intermediate to high-risk prostate adenocarcinoma, for a previously untreated patient who is considered suitable for locoregional therapy with curative intent. <u>Applicable once per lifetime</u>	Staging
	61564	<input type="checkbox"/> Restaging of recurrent prostate adenocarcinoma, for a patient who: (a) has undergone prior locoregional therapy; and (b) is considered suitable for further locoregional therapy to determine appropriate therapeutic pathways and timing of treatment initiation. <u>Applicable twice per lifetime.</u>	Restaging
	61528	<input type="checkbox"/> Assessment of suitability for Lutetium 177 PSMA therapy in a patient with metastatic castrate resistant prostate cancer, after progressive disease has developed while undergoing prior treatment with at least one taxane chemotherapy and at least one androgen receptor signalling inhibitor.	Post Lu-177 Therapy